



April 28, 2017

Notice of Annual General Meeting and Explanatory Memorandum

SYDNEY, Australia, April 28, 2017 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (OTC:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time)

NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM

Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on:

Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time)

Meeting to be held by teleconference (Dial-in details below):

United States	1 800 444 2801
Australia	02 9037 8402
New Zealand	0 800 440 176
Switzerland	0800 564 606
Netherlands	8000 220 915
United Kingdom	0 800 234 6984
Hong Kong	800 903 191

Participant Code: 5687312

For a link to the full Notice of Annual General Meeting and Explanatory Memorandum please click:

<http://www.globenewswire.com/NewsRoom/AttachmentNg/9bf785e5-da8b-4b60-a5d2-d71ace68e95e>

26 April 2017

Dear Shareholder,

On behalf of the Board of Directors of Parnell Pharmaceuticals Holdings Limited (ACN 137 904 413) (**Company**), I invite you to join us at our Annual General Meeting (**AGM**), which has been scheduled as follows:

Date: 29 May 2017 (CST), 30 May 2017 (AEST)

Time: 4:00 p.m. (CST), 7:00 a.m. (AEST)

Venue: Held by telephone conference (dial-in details above) or by physical attendance at:
Unit 4 Century Estate, 476 Gardeners Road, Alexandria, NSW, 2015

Outline of the items of business

At this AGM, we will provide an opportunity for shareholders to consider the following:

- | the Company's financial statements and related documents;
- | ratification of the appointment of the Company auditor; and
- | re-election of Dr. Alan Bell as a director of the Company.

Details of these items are contained in the enclosed Notice of AM and Explanatory Memorandum.

Voting at the AGM or by proxy

A proxy form accompanies the enclosed Notice of AGM. If you wish to attend the AGM in person, please bring a copy of the proxy form with you. Registration will be available from 3:30 p.m. (CST). If you are unable to attend in person, I encourage you to appoint a proxy to vote on the resolutions contained in the Notice of AGM on your behalf, by completing and returning the enclosed proxy form. Details of how to submit the proxy form are included with the form.

On behalf of all of the Directors, we look forward to hearing from you at the AGM.

Yours sincerely,

Alan Bell
Chairman

For more information, contact:

Parnell Pharmaceuticals Holdings

Robert Joseph, 913-274-2100

robert.joseph@parnell.com

Brad McCarthy, 913-274-2100

brad.mccarthy@parnell.com

 Primary Logo

Source: Parnell Pharmaceuticals Holdings Ltd

News Provided by Acquire Media